Connection

KAREN RABIN to Leukemia

This is a "connection" page, showing publications KAREN RABIN has written about Leukemia.
Connection Strength

0.998
  1. Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023 05; 37(5):1138-1140.
    View in: PubMed
    Score: 0.460
  2. Malignancy in children with trisomy 21. Oncologist. 2009 Feb; 14(2):164-73.
    View in: PubMed
    Score: 0.173
  3. Aberrant leukemia-associated immunophenotype as potential harbinger of lineage switch in KMT2A-rearranged leukemia: a case series. Leuk Lymphoma. 2020 12; 61(14):3515-3518.
    View in: PubMed
    Score: 0.097
  4. Utilization of archived neonatal dried blood spots for genome-wide genotyping. PLoS One. 2020; 15(2):e0229352.
    View in: PubMed
    Score: 0.093
  5. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.093
  6. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018 05 31; 131(22):2466-2474.
    View in: PubMed
    Score: 0.082
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.